文献速递主动脉疾病

围手术期输血与胸主动脉腔内修复术后30天死亡率和并发症恶化相关

Perioperative Blood Transfusion Is Associated with Worse 30-Day Mortality and Complications After Thoracic Endovascular Aortic Repair.
PubMed 文献 · Ann Vasc Surg · 2023-12-26

基于多中心血管质量倡议队列2010-2022年9263例胸主动脉腔内修复术(TEVAR)患者的回顾性研究,排除创伤、贫血、开放转换或破裂动脉瘤者。与未输血患者相比,围手术期输注1-3单位红细胞与30天死亡率、卒中、脊髓缺血、心肌梗死、充血性心力衰竭、呼吸系统并发症及任何术后并发症风险升高相关,输注≥4单位者风险更高。作者建议采取保守输血策略和多学科护理以识别并发症并救治接受任何量红细胞的患者,未来需研究输血患者结局机制。

要点

  • TEVAR围手术期输注1-3单位红细胞与30天死亡率风险约3倍升高相关(aRR 3.30)。
  • 输注≥4单位红细胞者上述并发症风险高于输注1-3单位者。
  • 作者建议保守输血策略和多学科护理以改善接受红细胞输注的TEVAR患者结局。

核心结论

  • 在血流动力学稳定、因非急诊/急诊非创伤适应症接受TEVAR的患者中,围手术期任何量的输血与30天死亡率、卒中、脊髓缺血、心肌梗死、充血性心力衰竭和呼吸系统并发症恶化相关。

研究设计与样本

  • 回顾性研究,纳入多中心血管质量倡议队列2010-2022年9263例接受TEVAR的患者,排除创伤后、贫血(世界卫生组织标准:女性血红蛋白<12 g/dl、男性<13 g/dl)、开放转换或破裂动脉瘤者。

主要发现

  • 与未输血患者(n=8223)相比,围手术期输注1-3单位红细胞(n=735)与30天死亡率风险升高约3倍相关(aRR 3.30,95%CI 2.39-4.57,P<0.001)。
  • 与未输血患者相比,输注1-3单位红细胞与卒中风险升高近2倍相关(aRR 1.98,95%CI 1.24-3.15,P=0.004),与脊髓缺血风险升高2.7倍相关(aRR 2.66,95%CI 1.87-3.77,P<0.001)。
  • 与未输血患者相比,输注1-3单位红细胞与心肌梗死风险升高3倍相关(aRR 3.40,95%CI 2.30-5.03,P<0.001),与充血性心力衰竭风险升高2倍相关(aRR 2.04,95%CI 1.09-3.83,P=0.03)。
  • 与未输血患者相比,输注1-3单位红细胞与呼吸系统并发症风险升高3.5倍相关(aRR 3.49,95%CI 2.67-4.56,P<0.001),与任何术后并发症风险升高2倍相关(aRR 2.36,95%CI 2.04-2.73,P<0.001)。
  • 输注4单位及以上红细胞(n=305)的患者上述效应高于输注1-3单位者,各组均与未输血患者比较。

临床怎么用

  • 作者认为,保守输血策略和多学科护理以识别并发症并救治围手术期接受任何量红细胞的TEVAR患者可能有助于改善结局。
  • 作者提出,未来需要研究以了解输血患者结局的机制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is not uncommon for patients requiring vascular surgery, and in particular aortic surgery, to have increased requirements for blood transfusion. However, studies examining the effects of perioperative transfusion for thoracic endovascular aortic repair (TEVAR) are limited. Using large multicenter data, we aimed to study the impact of perioperative blood transfusion on 30-day mortality and complications after TEVAR. METHODS: A total of 9,263 patients who underwent TEVAR were included in this retrospective study from the multicenter Vascular Quality Initiative cohort spanning 2010-2022. We excluded patients who were post-traumatic, anemic (World Health Organization criteria: hemoglobin < 12 g/dl and < 13 g/dl for females and males respectively), who underwent open conversions or presented with ruptured aneurysms. Primary outcomes were 30-day mortality and stroke. Secondary outcomes were postop congestive heart failure (CHF), respiratory complications, spinal cord ischemia (SCI), myocardial infarction (MI) and any postop complications (composite variable). Poisson regression with robust variance was performed to determine the risk of post op outcomes comparing patients who received red blood cells (RBCs) to those who did not. RESULTS: Comparing patients without any transfusion (n = 8,223), perioperative transfusion of 1-3 units (n = 735) was associated with 3-fold increased risk of 30-day mortality (adjusted relative risk [aRR] 3.30, 95% confidence interval [CI] 2.39,4.57, P < 0.001), almost 2-fold increased risk of stroke (aRR 1.98, 95% CI 1.24,3.15, P = 0.004), 2.7-fold increased risk of SCI (aRR 2.66, 95% CI 1.87-3.77, P < 0.001), 3-fold increased risk of MI (aRR 3.40, 95% CI 2.30, 5.03, P < 0.001), 2-fold increased risk of CHF (aRR 2.04, 95% CI 1.09, 3.83, P = 0.03), 3.5-fold increased risk of respiratory complications (aRR 3.49, 95% CI 2.67, 4.56, P < 0.001), and 2-fold increased risk of any postop complication (aRR 2.36, 95% CI 2.04, 2.73, P < 0.001). These effects were even higher in patients transfused 4 or more units (n = 305) than seen in the effects seen in those transfused 1-3 units; comparing each group to patients who received none. CONCLUSIONS: In hemodynamically stable patients undergoing TEVAR for nonemergent/emergent and nontraumatic indications, transfusion of any amount perioperatively is associated with worse 30-day mortality, stroke, SCI, MI, CHF, and respiratory complications. A conservative transfusion approach and multidisciplinary care to identify complications and rescue TEVAR patients who receive any amount of RBCs perioperatively might help improve outcomes. Future studies to understand the mechanisms of outcomes for transfused patients are needed.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Willie-Permor D, Real M, Zarrintan S, et al. Perioperative Blood Transfusion Is Associated with Worse 30-Day Mortality and Complications After Thoracic Endovascular Aortic Repair. Ann Vasc Surg. 2023. PMID: 38154494. doi:10.1016/j.avsg.2023.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。